January 30, 2026 09:18 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Big setback for Modi govt: Supreme Court stays controversial UGC Equity Regulations 2026 amid student protests | ‘Mother of all deals’: PM Modi says India–EU FTA is for 'ambitious India' | Delhi HC snubs Sameer Wankhede’s defamation plea over Aryan Khan's Netflix series | Maharashtra in shock: Ajit Pawar dies in plane crash — funeral sees emotional gathering of political heavyweights | India, Canada eye 10-year uranium pact during PM Carney’s March visit | 'None will be harassed': Dharmendra Pradhan breaks silence as UGC rules trigger student protests | Massive student uprising rocks Modi govt over new UGC rules on caste discrimination | Ajit Pawar no more: Maharashtra Deputy CM dies in Baramati plane crash | India, EU sign historic trade deal | ‘Dear Indian Friends’: Macron’s Republic Day message to India melts hearts
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.